Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 17, 2026, 6:52 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 17,839 matching trials from the live ClinicalTrials.gov search.
Conditions
Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, Multiple Myeloma
Interventions
cyclophosphamide, cyclosporine, Fludarabine, mycophenolate mofetil, total marrow irradiation, umbilical cord blood transplantation, Granulocyte colony-stimulating factor, HLA-matched related donor bone marrow
Drug · Radiation · Procedure + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 55 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Completed Phase 4 Interventional Accepts healthy volunteers Results available

CYP2B6 Genetics and Drug Interactions in Healthy Volunteers

NCT02401256
Conditions
Healthy
Interventions
Efavirenz, Bupropion, Rosuvastatin, Montelukast
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 49 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Waldenstrom Macroglobulinemia
Interventions
Pirtobrutinib, Venetoclax
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Clostridium Difficile Associated Disease
Interventions
Clostridium difficile Vaccine, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
65 Years to 85 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
17
States / cities
DeLand, Florida • Hollywood, Florida • South Miami, Florida + 11 more
Conditions
Prostate Cancer
Interventions
Aplidin (plitidepsin)
Drug
Lead sponsor
PharmaMar
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
2
States / cities
Ann Arbor, Michigan • Seattle, Washington
Conditions
Kaposi Sarcoma
Interventions
liposomal doxorubicin, pomalidomide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Low Back Pain
Interventions
Hydromorphone ER, Sugar pill
Drug
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Recurrent Ependymoma
Interventions
5-Azacytidine (5-AZA) group 1, 5-Azacytidine (5-AZA) group 2, 5-Azacytidine (5-AZA) group 3
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
1 Year to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Houston, Texas
Conditions
Hepatitis C
Interventions
Glecaprevir/pibrentasvir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years to 45 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
10
States / cities
Los Angeles, California • Aurora, Colorado • Jacksonville, Florida + 5 more
Conditions
Chronic Lymphocytic Leukemia, Lymphomas, Leukemias
Interventions
ABT-263
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
5
States / cities
Encinitas, California • Santa Monica, California • Bethesda, Maryland + 2 more
Conditions
Dry Eye Disease
Interventions
Lifitegrast/Perfluorohexyloctane Fixed Dose Combination, Lifitegrast, Perfluorohexyloctane, Vehicle
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
443 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
32
States / cities
Phoenix, Arizona • Glendale, California • Long Beach, California + 27 more
Conditions
Dry Eye Disease
Interventions
AG-80308
Drug
Lead sponsor
Allgenesis Biotherapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
3
States / cities
Newport Beach, California • Raynham, Massachusetts • Clinton, Utah
Conditions
Acute Ischemic Stroke
Interventions
High-definition Cathodal Transcranial Direct Current Stimulation (HD C-tDCS), Sham tDCS
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
3
States / cities
Los Angeles, California • Baltimore, Maryland • Durham, North Carolina
Conditions
Healthy Participants
Interventions
Elecoglipron, Atorvastatin, Rosuvastatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
2
States / cities
Glendale, California • Brooklyn, Maryland
Completed Phase 1Phase 2 Interventional Results available

Study of ASTX029 in Subjects With Advanced Solid Tumors

NCT03520075
Conditions
Solid Tumor, Adult
Interventions
ASTX029
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
19
States / cities
Duarte, California • Los Angeles, California • Newport Beach, California + 13 more
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Single Doses of SBT115301 in Healthy Participants

NCT05388981
Conditions
Safety
Interventions
SBT115301, Placebo
Biological
Lead sponsor
Sonoma Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Tempe, Arizona
Completed Phase 1 Interventional Accepts healthy volunteers

Autonomic Nervous System and Chronic Fatigue Syndrome

NCT00580619
Conditions
Chronic Fatigue Syndrome, Orthostatic Intolerance, Postural Tachycardia Syndrome
Interventions
Autonomic Function Testing, Saline infusions, L-NMMA trimethaphan, methyldopa
Other · Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 65 Years
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Contraception
Interventions
Testosterone, Nestorone®
Drug
Lead sponsor
Premier Research
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
2
States / cities
Torrance, California • Seattle, Washington
Conditions
Rheumatoid Arthritis
Interventions
INCB028050, Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
41
States / cities
Birmingham, Alabama • Paradise Valley, Arizona • Peoria, Arizona + 38 more
Conditions
Ewing's Family Tumors, Renal Tumors, Hepatoblastoma, Rhabdomyosarcoma, Soft Tissue Sarcoma, Primary Malignant Brain Neoplasms, Retinoblastoma, Medulloblastoma, Supra-tentorial Primative Neuro-Ectodermal Tumor (PNET), Atypical Teratoid/Rhabdoid Tumor (AT/RT), CNS Tumors, Germ Cell Tumors
Interventions
Ifosfamide, Etoposide, Mesna, G-CSF, Busulfan, Melphalan, Thiotepa, Autologous stem cell infusion, Radiation, Carboplatin, Paclitaxel, Leukapheresis, Anti-seizure prophylaxis, Ursodiol
Drug · Biological · Radiation + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 70 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Advanced Non Small Cell Lung Cancer
Interventions
Part A - AZD9291 in combination with AZD6094, Part A - AZD9291 in combination with continuous selumetinib (Asian subjects), Part A - AZD9291 in combination with continuous selumetinib (non-Asian subjects), Part A - AZD9291 in combination with intermittent selumetinib, Part A - AZD9291 in combination with MEDI4736, Part B - AZD9291 in combination with AZD6094, Part B - AZD9291 in combination with selumetinib, Part B - AZD9291 in combination with MEDI4736, Part C - AZD6094 monotherapy (Japan only), Part C - AZD9291 in combination with AZD6094 (Japan only), Part D - AZD9291 in combination with AZD6094
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
6
States / cities
Atlanta, Georgia • Boston, Massachusetts • New York, New York + 2 more
Conditions
Metastatic Pancreatic Cancer
Interventions
Ontak
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Maywood, Illinois
Conditions
Advanced Cancers, DLBCL, Lymphoma
Interventions
IONIS-STAT3Rx
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
9
States / cities
Scottsdale, Arizona • La Jolla, California • New Haven, Connecticut + 6 more
Conditions
Acute Coronary Syndrome
Interventions
Losmapimod, Moxifloxacin, Losmapimod matched Placebo, Moxifloxacin Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Baltimore, Maryland